5:59 PM
 | 
Oct 03, 2012
 |  BC Extra  |  Clinical News

Sarepta gains on additional DMD data

Sarepta Therapeutics Inc. (NASDAQ:SRPT) gained $29.94 (200%) to $44.93 on Wednesday after reporting additional data for eteplirsen to treat Duchenne muscular dystrophy (DMD). In an open-label extension of a Phase IIb trial, high-dose eteplirsen for 48 weeks led to significantly better clinical outcomes at week 48 compared to placebo for 24 weeks followed by...

Read the full 254 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >